Oncology Drug Reference Sheet: Epcoritamab-Bysp

Demonstrating a 61% overall response rate with 38% of patients achieving complete response, epcoritamab-bysp (Epkinly™) became the first CD20-bispecific antibody drug available for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when the U.S. Food and Drug Administration granted it accelerated approval in May 2023. A phase III trial is currently underway to confirm its clinical benefit compared to the current standard of care for relapsed or refractory DLBCL.